Molecular Pharmacology Program

The Neal Rosen Lab

Research

Pictured: Neal Rosen
Neal Rosen, MD, PhD

The main goal of our laboratory is the identification and characterization of signal transduction pathways that cause the dysregulation of growth and inhibition of apoptosis that characterize advanced human cancer. Our laboratory is dedicated to understanding the consequences of activation of these pathways and to using this information to develop mechanism-based therapeutic strategies.

View Lab Overview

Research Projects

Neal Rosen Lab Group

Publications Highlights

Lee BJ, Boyer JA, Burnett GL, Thottumkara AP, Tibrewal N, Wilson SL, Hsieh T, Marquez A, Lorenzana EG, Evans JW, Hulea L, Kiss G, Liu H, Lee D, Larsson O, McLaughlan S, Topisirovic I, Wang Z, Wang Z, Zhao Y, Wildes D, Aggen JB, Singh M, Gill AL, Smith JAM, Rosen N. Selective inhibitors of mTORC1 activate 4EBP1 and suppress tumor growth. Nat Chem Biol. 2021 Oct;17(10):1065-1074. doi: 10.1038/s41589-021-00813-7. Epub 2021 Jun 24. Erratum in: Nat Chem Biol. 2021 Jun 29;: Erratum in: Nat Chem Biol. 2021 Nov;17(11):1209. PMID: 34168367.

Mukherjee R, Vanaja KG, Boyer JA, Gadal S, Solomon H, Chandarlapaty S, Levchenko A, Rosen N. Regulation of PTEN translation by PI3K signaling maintains pathway homeostasis. Mol Cell. 2021 Feb 18;81(4):708-723.e5. doi: 10.1016/j.molcel.2021.01.033. PMID: 33606974; PMCID: PMC8384339.

Yao, Z., Gao, Y., Su, W., Yaeger, R., Tao, J., Na, N., Zhang, Y., Zhang, C., Rymar, A., Tao, A., Timaul, N. M., Mcgriskin, R., Outmezguine, N. A., Zhao, H., Chang, Q., Qeriqi, B., Barbacid, M., de Stanchina, E., Hyman, D. M., Bollag, G., … Rosen, N. (2019). RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling. Nature medicine, 25(2), 284–291. https://doi.org/10.1038/s41591-018-0274-5

Gao, Y., Chang, M. T., McKay, D., Na, N., Zhou, B., Yaeger, R., Torres, N. M., Muniz, K., Drosten, M., Barbacid, M., Caponigro, G., Stuart, D., Moebitz, H., Solit, D. B., Abdel-Wahab, O., Taylor, B. S., Yao, Z., & Rosen, N. (2018). Allele-Specific Mechanisms of Activation of MEK1 Mutants Determine Their Properties. Cancer discovery, 8(5), 648–661. https://doi.org/10.1158/2159-8290.CD-17-1452

Yaeger, R., Chatila, W. K., Lipsyc, M. D., Hechtman, J. F., Cercek, A., Sanchez-Vega, F., Jayakumaran, G., Middha, S., Zehir, A., Donoghue, M., You, D., Viale, A., Kemeny, N., Segal, N. H., Stadler, Z. K., Varghese, A. M., Kundra, R., Gao, J., Syed, A., Hyman, D. M., … Schultz, N. (2018). Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer. Cancer cell, 33(1), 125–136.e3. https://doi.org/10.1016/j.ccell.2017.12.004

View All Publications

People

Pictured: Neal Rosen

Neal Rosen, MD, PhD

  • Pharmacologist Neal Rosen focuses on understanding biochemical mechanisms underlying phenotypes caused by tyrosine kinase activation in epithelial tumors and developing new therapeutic strategies.
  • MD, PhD, Albert Einstein College of Medicine
[email protected]
Email Address
646-888-2075
Office Phone
View physician profile
Physician profile

Members

Jacob A. Boyer
Jacob A. Boyer

Ludwig Princeton Scholar in Cancer Metabolism at Princeton University, Princeton, NJ

Philip Choi

Research Fellow

Sunyana Gadal
Sunyana Gadal

Research Fellow

Esther Kaplun

Research Technician

Michelangelo Marasco

Research Fellow

Sandra Misale
Sandra Misale

Research Associate

Radha Mukherjee
Radha Mukherjee

Research Fellow

Priya Pancholi

Research Assistant

Malvika Sharma

Research Fellow

Hilla Solomon
Hilla Solomon

Research Associate

N. Merna Timaul
N. Merna Timaul

Lab Manager

Lab Alumni
Liqun Cai

Former Research Technician

Sarat Chandarlapaty

Assistant Member, Human Oncology and Pathogenesis Program; Department of Medicine, Memorial Sloan Kettering Cancer Center

Poulikos Poulikakos

Assistant Professor, Mount Sinai

Andreja Jovic

Research Fellow

Qing-Bai She

Faculty, University of Kentucky

Piro Lito
Piro Lito

Medical Oncology Fellow

David Solit

Director, Developmental Therapeutics; Associate Professor of Medicine; Cell and Developmental Biology, Memorial Sloan Kettering Cancer Center

Oren Litvin

Former Graduate Student

Christine A. Pratilas

Assistant Attending, Department of Pediatrics

Sarit Schwartz

Research Fellow

Martha Solomon

Research Technician

Sharmeen Uddin

Former Research Technician

Marie Will

Former Graduate Student

Paige Yellen

Research Fellow

Jingyin Yue

Former Research Fellow

Arpitha Banaji

Research Technician

Yu Bian

Former Research Technician

Laura Desrochers

Research Fellow

Yijun Gao
Yijun Gao

Research Associate

Alessandria Greco

Research Technician

Hidenori Kitai
Hidenori Kitai

Visiting Investigator

Rory Mcgriskin
Rory Mcgriskin

Medical Lab Assistant

Keven Muniz

Lab Technician

Na Na
Na Na

Research Technician

Virginia Ojeda Seijas
Virginia Ojeda Seijas

Research Fellow

Jason Reiter

Research Technician

Vanessa Rodrik-Outmezguine
Vanessa Rodrik-Outmezguine

Senior Scientist

Wenjing Su
Wenjing Su

Research Associate

Claire Thant
Claire Thant

Senior Research Technician

Alberto Vides

Research Technician

Adele Whaley
Adele Whaley
Jianing Xu
Jianing Xu

Research Associate

Rona Yaeger
Rona Yaeger

Assistant Attending Physician, Department of Medicine

Zhan Yao
Zhan Yao

Assistant Lab member

Lab Affiliations

Open Positions

To learn more about available postdoctoral opportunities, please visit our Career Center

To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs

Postdoctoral Positions

Apply now

Get in Touch

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Neal Rosen discloses the following relationships and financial interests:

  • Aadi Bioscience, Inc.
    Professional Services and Activities
  • BeiGene, Ltd.
    Equity; Professional Services and Activities
  • Chugai Pharmaceuticals
    Professional Services and Activities
  • Fortress Biotech Inc
    Equity
  • Ikena Oncology
    Professional Services and Activities
  • Jubilant Therapeutics Inc.
    Professional Services and Activities
  • Kura Oncology
    Equity
  • Lutris Pharma Ltd.
    Intellectual Property Rights
  • MapKure LLC
    Equity; Professional Services and Activities
  • Revolution Medicines
    Professional Services and Activities
  • Ribon Therapeutics
    Equity; Professional Services and Activities
  • Tokyo Biochemical Research Foundation - Comprehensive Academy for Advanced Oncology (TBRF-CHAAO)
    Professional Services and Activities
  • Zai Lab
    Equity; Professional Services and Activities
  • eFFECTOR Therapeutics
    Equity

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.


This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures